NCT02208297View on ClinicalTrials.gov

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
InflammationPainCataract
Interventions
DRUG

Loteprednol Etabonate Gel (BID)

One drop of LE gel instilled into the study eye two times per day (BID) for 14 days

DRUG

Vehicle Gel (BID)

One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days

Trial Locations (1)

08807

Bausch & Lomb Incorporated, Bridgewater

All Listed Sponsors
lead

Bausch & Lomb Incorporated

INDUSTRY

NCT02208297 - Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery | Biotech Hunter | Biotech Hunter